Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Oct;83(8):998–1002. doi: 10.1054/bjoc.2000.1359

Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity

V Misra 1, A Grondin 1, H J Klamut 1, A M Rauth 1
PMCID: PMC2363567  PMID: 10993645

Abstract

DT-diaphorase, a cytosolic reductase, has been implicated as an activator of chemotherapeutic prodrugs and a detoxifier of certain potentially carcinogenic xenobiotics. A common C to T nucleotide 609 substitution in DT-diaphorase cDNA has been associated with protein instability and reduced catalytic activity. The degree to which the allelic status of the substitution correlates with enzymatic activity was assessed in 45 normal human skin fibroblast strains using a PCR-RFLP assay. Included in this study was the 3437T strain, which is unique in that it is heterozygous for the polymorphism yet contains undetectable enzymatic activity. An allele-specific RT-PCR-RFLP technique attributed this phenomenon to exclusive DT-diaphorase mRNA expression from the variant allele. Overlap in activities was observed between individual strains homozygous for the wild-type allele and heterozygotes, but the former group displayed enzymatic activity that was on average 2-fold higher. Western blot analysis of the two strains in this panel that are homozygous for the variant allele revealed that they express relatively low amounts of DT-diaphorase protein, consistent with the role of the substitution in protein instability. This work confirms that genotypic status is a reliable initial estimate of DT-diaphorase activity. © 2000 Cancer Research Campaign

Keywords: DT-diaphorase, polymorphism, RT-PCR-RFLP, genotype, activity

Full Text

The Full Text of this article is available as a PDF (138.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begleiter A., Leith M. K., Curphey T. J., Doherty G. P. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncol Res. 1997;9(6-7):371–382. [PubMed] [Google Scholar]
  2. Chen H., Lum A., Seifried A., Wilkens L. R., Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609C-->T polymorphism with a decreased lung cancer risk. Cancer Res. 1999 Jul 1;59(13):3045–3048. [PubMed] [Google Scholar]
  3. Don R. H., Cox P. T., Wainwright B. J., Baker K., Mattick J. S. 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res. 1991 Jul 25;19(14):4008–4008. doi: 10.1093/nar/19.14.4008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Favreau L. V., Pickett C. B. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants. J Biol Chem. 1991 Mar 5;266(7):4556–4561. [PubMed] [Google Scholar]
  5. Goldberg Z. I., Cummings B. J., Chapman W. B., Klamut H. J., Rauth A. M. Role of a DT-diaphorase mutation in the response of anal canal carcinoma to radiation, 5-fluorouracil, and mitomycin C. Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):331–334. doi: 10.1016/s0360-3016(98)00234-x. [DOI] [PubMed] [Google Scholar]
  6. Jaiswal A. K. Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J Biol Chem. 1994 May 20;269(20):14502–14508. [PubMed] [Google Scholar]
  7. Kelsey K. T., Ross D., Traver R. D., Christiani D. C., Zuo Z. F., Spitz M. R., Wang M., Xu X., Lee B. K., Schwartz B. S. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76(7):852–854. doi: 10.1038/bjc.1997.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kuehl B. L., Paterson J. W., Peacock J. W., Paterson M. C., Rauth A. M. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 1995 Sep;72(3):555–561. doi: 10.1038/bjc.1995.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Marshall R. S., Paterson M. C., Rauth A. M. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis. 1991 Jul;12(7):1175–1180. doi: 10.1093/carcin/12.7.1175. [DOI] [PubMed] [Google Scholar]
  10. Misra V., Klamut H. J., Rauth A. M. Transfection of COS-1 cells with DT-diaphorase cDNA: role of a base change at position 609. Br J Cancer. 1998 Apr;77(8):1236–1240. doi: 10.1038/bjc.1998.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nebert D. W., Ingelman-Sundberg M., Daly A. K. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev. 1999 May;31(2):467–487. doi: 10.1081/dmr-100101931. [DOI] [PubMed] [Google Scholar]
  12. Radjendirane V., Joseph P., Lee Y. H., Kimura S., Klein-Szanto A. J., Gonzalez F. J., Jaiswal A. K. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem. 1998 Mar 27;273(13):7382–7389. doi: 10.1074/jbc.273.13.7382. [DOI] [PubMed] [Google Scholar]
  13. Schlager J. J., Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990 Mar 15;45(3):403–409. doi: 10.1002/ijc.2910450304. [DOI] [PubMed] [Google Scholar]
  14. Siegel D., McGuinness S. M., Winski S. L., Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999 Feb;9(1):113–121. doi: 10.1097/00008571-199902000-00015. [DOI] [PubMed] [Google Scholar]
  15. Traver R. D., Horikoshi T., Danenberg K. D., Stadlbauer T. H., Danenberg P. V., Ross D., Gibson N. W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992 Feb 15;52(4):797–802. [PubMed] [Google Scholar]
  16. Traver R. D., Siegel D., Beall H. D., Phillips R. M., Gibson N. W., Franklin W. A., Ross D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;75(1):69–75. doi: 10.1038/bjc.1997.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Warrington K. H., Jr, Teschendorf C., Cao L., Muzyczka N., Siemann D. W. Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid. Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):909–912. doi: 10.1016/s0360-3016(98)00357-5. [DOI] [PubMed] [Google Scholar]
  18. Wiemels J. L., Pagnamenta A., Taylor G. M., Eden O. B., Alexander F. E., Greaves M. F. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res. 1999 Aug 15;59(16):4095–4099. [PubMed] [Google Scholar]
  19. Workman P., Stratford I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 1993 Jun;12(2):73–82. doi: 10.1007/BF00689802. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES